obesity
Obesity is a chronic, progressive, relapsing disease defined by abnormal or excess adiposity that impairs health — not by BMI alone. Ask permission to discuss weight (5As framework), assess central adiposity (waist circumference, waist-to-hip or waist-to-height ratio) alongside ethnicity-specific BMI and the Edmonton Obesity Staging System, and replace weight-promoting drugs where possible. Offer long-term pharmacotherapy (BMI ≥30 or ≥27 with adiposity-related complications; semaglutide 2.4 mg or tirzepatide preferred for potency and organ-specific outcomes) and consider bariatric surgery at BMI ≥40, ≥35 with comorbidity, or 30–35 with poorly controlled type 2 diabetes.
assessment and staging (OC 2020; 2025)
- Ask permission before discussing weight or taking anthropometric measurements; use non-stigmatising, person-first language (“person living with obesity”)
- Anthropometrics: measure height, weight, BMI, and central adiposity (waist circumference, waist-to-hip ratio, or waist-to-height ratio) using sex- and ethnicity-specific thresholds (Obesity Canada 2025 R1 — South Asian/East Asian populations carry cardiometabolic risk at lower BMI)
- Edmonton Obesity Staging System (EOSS): stages severity from 0 (no risk factors/functional limits) to 4 (end-stage adiposity-related disability) — predicts mortality better than BMI alone
- Baseline cardiometabolic & comorbidity screen: BP in both arms, fasting glucose or HbA1c, lipid profile, ALT (for MASLD/MASH), OSA screening, osteoarthritis, PCOS, mental health/eating disorders, and age-appropriate cancer screening (excess adiposity increases risk of colorectal, endometrial, postmenopausal breast, renal, and oesophageal cancers)
- Pillars of care: individualised medical nutrition therapy (registered dietitian) + physical activity (30–60 min moderate–vigorous aerobic activity most days + resistance training to preserve lean mass) + multicomponent psychological/behavioural support — augmented by pharmacotherapy and/or bariatric surgery
pharmacotherapy (OC 2025 update)
Offer long-term alongside health behaviour changes for BMI ≥30 or BMI ≥27 with adiposity-related complications (or equivalent ethnicity-specific BMI / central adiposity threshold). Long-term continuation is required to prevent weight regain and loss of cardiometabolic benefit.
| agent | dosing | key indications & organ-specific benefits (2025 update) | key adverse effects / cautions |
|---|---|---|---|
| semaglutide | 2.4 mg SC weekly | weight loss (~15%), MACE reduction in established ASCVD (BMI ≥27), HFpEF symptoms/events (BMI ≥30), MASH resolution & fibrosis improvement, knee OA pain reduction (BMI ≥30), normoglycaemia in prediabetes, type 2 diabetes | GI upset (slow titration), gallstones; avoid in personal/family MTC/MEN2 (see glp-1 receptor agonists) |
| tirzepatide | 5, 10, or 15 mg SC weekly | weight loss (~15–21%), HFpEF CV death/worsening HF reduction (15 mg, BMI ≥30), moderate–severe OSA AHI reduction with or without PAP (10–15 mg, BMI ≥30), MASH resolution/fibrosis, prediabetes progression reduction, type 2 diabetes | GI upset, gallstones; reduces oral contraceptive efficacy for 4 wk after start & each dose increase; avoid in MTC/MEN2 |
| liraglutide | 3.0 mg SC daily | weight loss (~6–8%), prediabetes progression reduction, type 2 diabetes, OSA (unwilling/unable to use PAP), MASH (1.8 mg) | daily injection, GI upset, gallstones |
| naltrexone–bupropion | 16 mg/180 mg PO BID (titrated) | weight loss (~5–6%), type 2 diabetes, useful if coexisting smoking/cravings | nausea, ↑ BP/HR; avoid in uncontrolled HTN, seizure disorder, eating disorder, chronic opioid use, MAOIs |
| orlistat | 120 mg PO TID with meals | weight loss (~3–5%), prediabetes progression reduction, type 2 diabetes, weight maintenance | oily spotting, faecal urgency, fat-soluble vitamin (A, D, E, K) malabsorption (take multivitamin ≥2 h apart), oxalate nephrolithiasis |
- Monogenic obesity (2025): setmelanotide (MC4R agonist, up to 3 mg SC daily) for BMI ≥30 with Bardet–Biedl syndrome or biallelic POMC, PCSK1, or LEPR deficiency
- Avoid compounded or unapproved agents: Obesity Canada 2025 recommends against compounded GLP-1s or off-label/OTC weight-loss products (R13)
- Antipsychotic-induced weight gain: consider metformin and CBT to prevent weight gain in severe mental illness on high-risk antipsychotics; consider lisdexamfetamine or topiramate as adjuncts to psychotherapy in binge-eating disorder (Obesity Canada 2020)
medications causing weight gain and alternatives
| drug class | agents promoting weight gain | weight-neutral / weight-loss alternatives |
|---|---|---|
| antipsychotics | olanzapine, clozapine, quetiapine, risperidone, haloperidol | aripiprazole, ziprasidone, lurasidone |
| antidepressants / mood | mirtazapine, TCAs (amitriptyline, nortriptyline), paroxetine, citalopram, lithium | bupropion, fluoxetine, sertraline, duloxetine, venlafaxine |
| anticonvulsants | valproate, carbamazepine, gabapentin, pregabalin | topiramate, lamotrigine |
| antihyperglycaemics | insulin, sulfonylureas, thiazolidinediones | metformin, glp-1 receptor agonists, SGLT2 inhibitors, DPP-4i |
| antihypertensives | β-blockers (especially propranolol) | ACEi, ARB, CCB |
| steroids / antihistamines | systemic glucocorticoids, 1st-generation antihistamines | steroid-sparing therapy, 2nd-generation antihistamines |
bariatric surgery (OC 2020)
indications and procedure selection
- Consider referral for:
- BMI ≥40 (without comorbidity)
- BMI ≥35 with ≥1 adiposity-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, OSA, obesity hypoventilation, MASLD/MASH, severe GERD, debilitating OA, idiopathic intracranial hypertension)
- BMI 30–35 with poorly controlled type 2 diabetes despite optimal medical therapy (Grade A), or other adiposity-related disease refractory to medical/behavioural care
- Procedures: sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB) (duodenal switch in selected severe obesity). Avoid adjustable gastric banding (high complication/failure rates) and routine single-anastomosis gastric bypass
- Pre-operative workup: multidisciplinary medical/nutritional/psychological evaluation, correct baseline micronutrient deficiencies, screen/treat OSA, smoking cessation (reduces marginal ulcer and surgical complications)
post-operative complications and long-term monitoring
- Surgical/GI: anastomotic leak/bleed, stomal obstruction, internal hernia, gallstones, marginal ulcer (avoid NSAIDs and smoking after RYGB), dumping syndrome (early autonomic/GI symptoms; late post-bariatric hypoglycaemia 1–3 h post-meal)
- Nutritional deficiencies (higher with RYGB/duodenal switch than sleeve): iron, vitamin B12, folate, calcium (use calcium citrate — does not require gastric acid), vitamin D, thiamine (B1) (vomiting → Wernicke encephalopathy — treat empirically!), fat-soluble vitamins (A, D, E, K), copper, zinc
- Lifelong follow-up: daily multivitamin + targeted supplements, annual lab monitoring (CBC, ferritin/iron, B12, folate, Ca²⁺, PTH, 25-OH vitamin D, albumin), bone density/fracture monitoring (secondary hyperparathyroidism and bone loss are common — see osteoporosis), and prompt de-escalation of insulin, sulfonylureas, and antihypertensives post-op to prevent hypoglycaemia and hypotension
Prepared 2026-11-19. Not yet verified — check every number against the sources.